Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
March 28 2024 - 8:30AM
Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical
company focused on advancing the next wave of medicine for
inflammatory diseases, today announced the appointment of Geoff
McDonough, M.D., to its Board of Directors.
“Geoff is an outstanding addition to our board, bringing broad
operational leadership and a depth of clinical and commercial
experience that will benefit our work greatly as we advance our
lead product candidate, THB335, into clinical trials for chronic
spontaneous urticaria,” said Natalie Holles, Chief Executive
Officer of Third Harmonic Bio. “Beyond his expertise, Geoff is an
excellent cultural fit with our organization, bringing a passion
for people development and company building as we advance Third
Harmonic Bio as the recognized leader in the field of mast-cell
mediated inflammatory diseases.”
Dr. McDonough is currently President and Chief Executive Officer
and serves on the Board of Directors of Generation Bio Co. Prior to
this role, he served as the President and Chief Executive Officer
of Swedish Orphan Biovitrum AB (Sobi) from 2011 to 2017. Before
Sobi, he held various senior roles at Genzyme Corporation,
including the President of Genzyme Europe and Senior Vice President
and General Manager of the global lysosomal storage disease
business. Dr. McDonough obtained his M.D. at Harvard Medical School
and completed residency training in internal medicine and
pediatrics at Massachusetts General Hospital and Boston Children's
Hospital.
“Third Harmonic Bio is poised to enter the clinic with a KIT
inhibitor that has the potential to make a positive impact in the
lives of patients living with chronic spontaneous urticaria,” said
Dr. McDonough. “I am excited to join the exceptional team at Third
Harmonic Bio in working to expand the treatment landscape for mast
cell disorders.”
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a biopharmaceutical company focused on
advancing the next wave of medicine for inflammatory diseases
through the development of novel, highly selective, small-molecule
inhibitors of KIT, a cell surface receptor that serves as the
master regulator of mast cell function and survival. Early clinical
studies demonstrate that KIT inhibition has the potential to
revolutionize the treatment of a broad range of mast-cell-mediated
inflammatory diseases, and that a titratable, oral small molecule
inhibitor may provide the optimal therapeutic profile against this
target. Third Harmonic Bio’s lead product candidate, THB335, is a
titratable, oral small molecule inhibitor expected to enter
clinical trials during the second quarter of 2024. For more
information, please visit the Third Harmonic Bio website:
www.thirdharmonicbio.com.
Forward-Looking Statement
This press release contains “forward-looking” statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, including, but not
limited to, the expected timing for clinical activities for THB335.
Forward-looking statements can be identified by words such as:
“anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,”
“project,” “estimate,” “expect,” “strategy,” “future,” “likely,”
“may,” “should,” “will” and similar references to future periods.
These statements are subject to numerous risks and uncertainties,
including risks and uncertainties related to Third Harmonic Bio’s
cash forecasts, ability to advance its product candidates, the
receipt and timing of potential regulatory submissions,
designations, approvals and commercialization of product
candidates, our ability to protect our intellectual property, the
timing and results of preclinical and clinical trials, changes to
laws or regulations, market conditions, geopolitical events, and
further impacts of pandemics or health epidemics, that could cause
actual results to differ materially from what Third Harmonic Bio
expects. Further information on potential risk factors that could
affect Third Harmonic Bio’s business and its financial results are
detailed under the heading “Risk Factors” included in Third
Harmonic Bio’s Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the U.S. Securities and Exchange
Commission (SEC) on March 26, 2024, and in Third Harmonic Bio’s
other filings filed from time to time with the SEC. Third Harmonic
Bio undertakes no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor and Media Contact:Lori
Murraylori.murray@thirdharmonicbio.com
Investor & Media Contact: Lori
Murray lori.murray@thirdharmonicbio.com
Third Harmonic Bio (NASDAQ:THRD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Third Harmonic Bio (NASDAQ:THRD)
Historical Stock Chart
From Aug 2023 to Aug 2024